Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Retained Earnings (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Retained Earnings for 3 consecutive years, with -$1.2 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 28.51% to -$1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Dec 2025, up 28.51% year-over-year, with the annual reading at -$1.2 million for FY2025, 28.51% up from the prior year.
  • Retained Earnings hit -$1.2 million in Q4 2025 for Connect Biopharma Holdings, up from -$1.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$1.0 million in Q4 2023 to a low of -$1.7 million in Q4 2024.
  • Historically, Retained Earnings has averaged -$1.4 million across 3 years, with a median of -$1.3 million in 2025.
  • Biggest five-year swings in Retained Earnings: crashed 65.28% in 2024 and later increased 28.51% in 2025.
  • Year by year, Retained Earnings stood at -$1.0 million in 2023, then crashed by 65.28% to -$1.7 million in 2024, then increased by 28.51% to -$1.2 million in 2025.
  • Business Quant data shows Retained Earnings for CNTB at -$1.2 million in Q4 2025, -$1.3 million in Q3 2025, and -$1.4 million in Q2 2025.